panitumumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4955	339177-26-3

Description:

Molecule	Description
Synonyms: panitumumab vectibix ABX-EGF	Recombinant human monoclonal antibody that binds to and inhibits the function of the EPIDERMAL GROWTH FACTOR RECEPTOR. It is used in the treatment of EGFR-expressing metastatic colorectal cancer that expresses wild-type ras gene (see GENES, RAS). Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

panitumumab
vectibix
ABX-EGF

Recombinant human monoclonal antibody that binds to and inhibits the function of the EPIDERMAL GROWTH FACTOR RECEPTOR. It is used in the treatment of EGFR-expressing metastatic colorectal cancer that expresses wild-type ras gene (see GENES, RAS).

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 3, 2007	EMA	Amgen Europe B.V.
Sept. 27, 2006	FDA	AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	972.71	27.11	209	9060	3848	50592007
Skin toxicity	490.83	27.11	119	9150	3794	50592061
Paronychia	482.59	27.11	121	9148	4443	50591412
Hypomagnesaemia	365.36	27.11	143	9126	23013	50572842
Dry skin	262.50	27.11	137	9132	43054	50552801
Stomatitis	213.02	27.11	164	9105	101180	50494675
Rash	206.39	27.11	320	8949	437151	50158704
Neutropenia	198.80	27.11	185	9084	147780	50448075
Disease progression	190.27	27.11	150	9119	95716	50500139
Skin fissures	174.38	27.11	64	9205	8604	50587251
Neuropathy peripheral	161.68	27.11	137	9132	96620	50499235
Diarrhoea	157.83	27.11	337	8932	588139	50007716
Rash pustular	119.87	27.11	45	9224	6436	50589419
Skin disorder	111.92	27.11	64	9205	23966	50571889
Metastases to liver	105.74	27.11	58	9211	20046	50575809
Neurotoxicity	101.70	27.11	51	9218	14689	50581166
Palmar-plantar erythrodysaesthesia syndrome	100.27	27.11	56	9213	20042	50575813
Skin reaction	91.68	27.11	44	9225	11524	50584331
Neutrophil count decreased	84.69	27.11	69	9200	45957	50549898
Mucosal inflammation	84.19	27.11	65	9204	40077	50555778
Peripheral sensory neuropathy	84.12	27.11	35	9234	6556	50589299
Thrombocytopenia	79.48	27.11	107	9162	127566	50468289
Drug ineffective	79.33	27.11	26	9243	819307	49776548
Xerosis	67.82	27.11	17	9252	620	50595235
Therapy partial responder	67.64	27.11	30	9239	6561	50589294
Hypertrichosis	64.62	27.11	18	9251	991	50594864
Polyneuropathy	61.03	27.11	34	9235	12097	50583758
Malignant neoplasm progression	59.94	27.11	68	9201	68056	50527799
Hypokalaemia	58.18	27.11	76	9193	87916	50507939
Acne	57.70	27.11	39	9230	19556	50576299
Hypocalcaemia	55.28	27.11	43	9226	26773	50569082
Trichomegaly	53.78	27.11	9	9260	37	50595818
Decreased appetite	53.16	27.11	115	9154	200808	50395047
Blood magnesium decreased	52.67	27.11	30	9239	11130	50584725
Febrile neutropenia	50.56	27.11	75	9194	97592	50498263
Dehydration	48.26	27.11	94	9175	152355	50443500
Colorectal cancer metastatic	46.25	27.11	12	9257	503	50595352
Anaemia	45.89	27.11	125	9144	252331	50343524
Erythema	44.79	27.11	89	9180	146325	50449530
Ileal perforation	44.51	27.11	11	9258	378	50595477
Leukopenia	42.57	27.11	57	9212	67471	50528384
Arthralgia	42.13	27.11	14	9255	438688	50157167
Carcinoembryonic antigen increased	41.56	27.11	14	9255	1460	50594395
Growth of eyelashes	41.08	27.11	9	9260	180	50595675
Death	38.65	27.11	139	9130	325240	50270615
Conjunctivitis	37.93	27.11	28	9241	16117	50579738
Fall	37.21	27.11	8	9261	334924	50260931
Ileus	35.80	27.11	25	9244	13204	50582651
Dermatitis	34.12	27.11	25	9244	14226	50581629
Pain of skin	33.88	27.11	20	9249	7927	50587928
Interstitial lung disease	33.68	27.11	45	9224	53131	50542724
Xeroderma	33.67	27.11	7	9262	108	50595747
Headache	32.69	27.11	27	9242	506508	50089347
Eye irritation	32.13	27.11	26	9243	17114	50578741
Gastrointestinal toxicity	31.71	27.11	16	9253	4661	50591194
Metastases to lung	30.22	27.11	21	9248	10999	50584856
Abdominal discomfort	29.06	27.11	4	9265	231637	50364218
Large intestine perforation	27.17	27.11	17	9252	7477	50588378

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	1809.22	24.14	442	14481	5049	29554555
Paronychia	1018.83	24.14	247	14676	2706	29556898
Skin toxicity	828.57	24.14	220	14703	3551	29556053
Hypomagnesaemia	607.15	24.14	253	14670	17215	29542389
Rash	480.68	24.14	531	14392	189288	29370316
Skin reaction	349.08	24.14	117	14806	4300	29555304
Stomatitis	319.99	24.14	211	14712	36902	29522702
Rash pustular	318.88	24.14	111	14812	4580	29555024
Interstitial lung disease	296.80	24.14	240	14683	57478	29502126
Disease progression	246.38	24.14	252	14671	81664	29477940
Dry skin	236.65	24.14	147	14776	23160	29536444
Diarrhoea	221.81	24.14	504	14419	332194	29227410
Metastases to liver	213.71	24.14	109	14814	11747	29547857
Neutropenia	190.70	24.14	280	14643	131431	29428173
Neuropathy peripheral	189.32	24.14	205	14718	70822	29488782
Acne	184.49	24.14	91	14832	9129	29550475
Skin disorder	175.74	24.14	95	14828	11523	29548081
Folliculitis	150.55	24.14	61	14862	3839	29555765
Mucosal inflammation	134.49	24.14	118	14805	31477	29528127
Skin fissures	116.81	24.14	51	14872	3868	29555736
Conjunctivitis	111.53	24.14	62	14861	7936	29551668
Therapy partial responder	109.02	24.14	53	14870	5146	29554458
Decreased appetite	108.21	24.14	231	14692	145111	29414493
Drug ineffective	94.44	24.14	33	14890	363137	29196467
Metastases to lung	93.71	24.14	55	14868	7800	29551804
Carcinoembryonic antigen increased	93.53	24.14	27	14896	597	29559007
Neutrophil count decreased	89.37	24.14	110	14813	43457	29516147
Neurotoxicity	86.15	24.14	66	14857	14547	29545057
Xerosis	86.08	24.14	24	14899	466	29559138
Palmar-plantar erythrodysaesthesia syndrome	83.38	24.14	65	14858	14694	29544910
Hypocalcaemia	79.62	24.14	73	14850	20592	29539012
Polyneuropathy	74.08	24.14	56	14867	12096	29547508
Peripheral sensory neuropathy	71.93	24.14	42	14881	5897	29553707
Blood magnesium decreased	67.60	24.14	39	14884	5355	29554249
Drug interaction	58.38	24.14	14	14909	197371	29362233
Erythema	58.21	24.14	122	14801	75484	29484120
Thrombocytopenia	56.87	24.14	173	14750	134650	29424954
Dermatitis	56.74	24.14	40	14883	7758	29551846
Trichomegaly	54.62	24.14	10	14913	21	29559583
Headache	54.15	24.14	11	14912	173996	29385608
Ileus	51.84	24.14	49	14874	14353	29545251
Colorectal cancer metastatic	48.85	24.14	16	14907	545	29559059
Growth of eyelashes	46.93	24.14	10	14913	57	29559547
Dehydration	46.27	24.14	145	14778	114603	29445001
Arthralgia	45.18	24.14	8	14915	139609	29419995
Pulmonary embolism	43.93	24.14	110	14813	76424	29483180
Metastases to lymph nodes	42.39	24.14	26	14897	3991	29555613
Metastases to pelvis	41.66	24.14	12	14911	263	29559341
Perioral dermatitis	40.97	24.14	10	14913	112	29559492
Hepatectomy	40.28	24.14	9	14914	66	29559538
Intestinal obstruction	40.01	24.14	49	14874	19228	29540376
Catheter site thrombosis	39.49	24.14	8	14915	34	29559570
Metastases to peritoneum	36.45	24.14	17	14906	1503	29558101
Carbohydrate antigen 19-9 increased	36.42	24.14	10	14913	183	29559421
Somnolence	36.19	24.14	3	14920	93952	29465652
Febrile neutropenia	34.00	24.14	129	14794	112111	29447493
Fall	33.98	24.14	24	14899	177154	29382450
Gastrointestinal toxicity	33.81	24.14	18	14905	2113	29557491
Toxicity to various agents	32.68	24.14	24	14899	173637	29385967
Product dose omission issue	32.32	24.14	5	14918	96378	29463226
Livedo reticularis	31.34	24.14	17	14906	2071	29557533
Hypertrichosis	30.77	24.14	10	14913	332	29559272
Nail disorder	30.62	24.14	16	14907	1808	29557796
Ectropion	29.58	24.14	7	14916	68	29559536
Acne pustular	29.13	24.14	7	14916	73	29559531
Skin exfoliation	28.15	24.14	45	14878	22600	29537004
Epidermal naevus syndrome	27.82	24.14	5	14918	9	29559595
Dermatitis infected	27.58	24.14	7	14916	93	29559511
Overdose	27.08	24.14	4	14919	79815	29479789
Myocardial infarction	26.89	24.14	11	14912	110285	29449319
Dizziness	26.65	24.14	34	14889	189650	29369954
Eyelash changes	26.56	24.14	5	14918	13	29559591
Device related infection	26.56	24.14	36	14887	15600	29544004
Enterocolitis	26.54	24.14	24	14899	6642	29552962
Vena cava thrombosis	26.33	24.14	12	14911	1006	29558598
Cough	25.86	24.14	16	14907	126711	29432893
Cardiac failure congestive	25.61	24.14	4	14919	76577	29483027
Drug effective for unapproved indication	25.10	24.14	13	14910	1442	29558162
Confusional state	24.93	24.14	17	14906	127860	29431744
Myalgia	24.45	24.14	4	14919	74015	29485589

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	2500.69	22.88	571	19917	7872	64470372
Paronychia	1268.50	22.88	314	20174	6178	64472066
Skin toxicity	1079.67	22.88	277	20211	6325	64471919
Hypomagnesaemia	751.63	22.88	321	20167	37055	64441189
Stomatitis	467.34	22.88	338	20150	109267	64368977
Rash	438.14	22.88	626	19862	457923	64020321
Disease progression	429.73	22.88	357	20131	141323	64336921
Dry skin	418.27	22.88	238	20250	50923	64427321
Neuropathy peripheral	393.89	22.88	314	20174	117211	64361033
Rash pustular	357.57	22.88	130	20358	9755	64468489
Interstitial lung disease	355.18	22.88	274	20214	97458	64380786
Neutropenia	327.41	22.88	391	20097	239233	64239011
Metastases to liver	299.41	22.88	148	20340	23793	64454451
Diarrhoea	298.58	22.88	685	19803	722019	63756225
Skin reaction	270.94	22.88	113	20375	12239	64466005
Skin disorder	251.16	22.88	138	20350	27542	64450702
Skin fissures	211.71	22.88	90	20398	10216	64468028
Acne	206.43	22.88	114	20374	22967	64455277
Therapy partial responder	192.46	22.88	84	20404	10164	64468080
Mucosal inflammation	185.72	22.88	156	20332	62428	64415816
Palmar-plantar erythrodysaesthesia syndrome	185.46	22.88	115	20373	28704	64449540
Neutrophil count decreased	166.96	22.88	161	20327	77035	64401209
Neurotoxicity	165.39	22.88	105	20383	27299	64450945
Thrombocytopenia	150.43	22.88	261	20227	223540	64254704
Decreased appetite	148.95	22.88	296	20192	280993	64197251
Polyneuropathy	142.39	22.88	85	20403	19809	64458435
Metastases to lung	127.21	22.88	72	20416	15192	64463052
Peripheral sensory neuropathy	117.92	22.88	62	20426	11316	64466928
Carcinoembryonic antigen increased	116.44	22.88	37	20451	1836	64476408
Drug ineffective	113.97	22.88	63	20425	840184	63638060
Conjunctivitis	110.53	22.88	73	20415	20281	64457963
Hypocalcaemia	109.44	22.88	97	20391	41656	64436588
Trichomegaly	92.21	22.88	17	20471	70	64478174
Hypertrichosis	89.61	22.88	27	20461	1121	64477123
Headache	85.22	22.88	31	20457	529436	63948808
Arthralgia	81.85	22.88	20	20468	442240	64036004
Xerosis	80.68	22.88	24	20464	953	64477291
Dermatitis	75.21	22.88	55	20433	17974	64460270
Ileus	73.79	22.88	60	20428	22906	64455338
Colorectal cancer metastatic	68.19	22.88	21	20467	939	64477305
Drug interaction	67.70	22.88	16	20472	362067	64116177
Fall	64.36	22.88	26	20462	416800	64061444
Leukopenia	61.32	22.88	113	20375	101129	64377115
Erythema	61.17	22.88	163	20325	186907	64291337
Febrile neutropenia	54.89	22.88	157	20331	187500	64290744
Blood magnesium decreased	50.39	22.88	39	20449	13866	64464378
Metastases to lymph nodes	49.10	22.88	32	20456	8685	64469559
Ectropion	48.58	22.88	13	20475	349	64477895
Pain	48.48	22.88	63	20425	553448	63924796
Malignant neoplasm progression	48.18	22.88	109	20379	112762	64365482
Carbohydrate antigen 19-9 increased	47.99	22.88	13	20475	366	64477878
Product dose omission issue	46.99	22.88	4	20484	194743	64283501
Hypokalaemia	46.88	22.88	113	20375	121790	64356454
Hepatectomy	46.56	22.88	11	20477	175	64478069
Peripheral swelling	46.10	22.88	6	20482	209147	64269097
Folliculitis	45.70	22.88	52	20436	30025	64448219
Intestinal obstruction	44.10	22.88	56	20432	36230	64442014
Gastrointestinal toxicity	44.05	22.88	25	20463	5297	64472947
Growth of eyelashes	43.99	22.88	10	20478	133	64478111
Toxicity to various agents	42.58	22.88	32	20456	363481	64114763
Depression	41.02	22.88	5	20483	183286	64294958
Death	40.53	22.88	277	20211	482428	63995816
Dermatitis infected	39.84	22.88	10	20478	207	64478037
Pulmonary embolism	39.47	22.88	119	20369	146237	64332007
Pain in extremity	39.06	22.88	24	20464	303061	64175183
Metastases to peritoneum	38.66	22.88	20	20468	3527	64474717
Somnolence	38.01	22.88	9	20479	203636	64274608
Nasopharyngitis	37.94	22.88	8	20480	196065	64282179
Confusional state	37.55	22.88	18	20470	261126	64217118
Ileal perforation	36.97	22.88	13	20475	883	64477361
Skin exfoliation	34.91	22.88	56	20432	44829	64433415
Product use issue	34.28	22.88	4	20484	151711	64326533
Cough	33.60	22.88	28	20460	302120	64176124
Dysgeusia	32.96	22.88	56	20432	46991	64431253
Perioral dermatitis	32.87	22.88	9	20479	264	64477980
Dizziness	32.68	22.88	54	20434	430109	64048135
Livedo reticularis	32.32	22.88	18	20470	3679	64474565
Mucocutaneous rash	32.11	22.88	6	20482	27	64478217
Hyperammonaemia	32.07	22.88	26	20462	9878	64468366
Thrombocytopenic purpura	31.95	22.88	15	20473	2147	64476097
Haematotoxicity	31.87	22.88	29	20459	12867	64465377
Metastases to pelvis	30.87	22.88	10	20478	528	64477716
Cardiac failure congestive	30.64	22.88	3	20485	130577	64347667
Epidermal naevus syndrome	30.13	22.88	5	20483	9	64478235
Overdose	29.88	22.88	7	20481	159559	64318685
Drug effective for unapproved indication	29.57	22.88	17	20471	3691	64474553
Gene mutation	29.40	22.88	14	20474	2068	64476176
Abdominal discomfort	28.70	22.88	11	20477	182311	64295933
Pain of skin	28.69	22.88	24	20464	9523	64468721
Musculoskeletal stiffness	28.46	22.88	3	20485	123203	64355041
Swelling	28.14	22.88	8	20480	160210	64318034
Device related infection	27.73	22.88	41	20447	30585	64447659
Drug hypersensitivity	27.73	22.88	21	20467	237794	64240450
Enterocolitis	27.71	22.88	26	20462	11992	64466252
Metastasis	27.50	22.88	19	20469	5676	64472568
Blepharitis	26.69	22.88	14	20474	2541	64475703
Nail disorder	26.58	22.88	22	20466	8602	64469642
Neoplasm progression	26.40	22.88	47	20441	40917	64437327
Colorectal cancer	26.31	22.88	15	20473	3206	64475038
Catheter site thrombosis	26.09	22.88	7	20481	190	64478054
Xeroderma	25.64	22.88	7	20481	203	64478041
Dehydration	25.53	22.88	136	20352	216627	64261617
Ascites	25.47	22.88	59	20429	61942	64416302
Drug intolerance	25.46	22.88	14	20474	187978	64290266
Eye irritation	25.08	22.88	28	20460	15828	64462416
Insomnia	25.01	22.88	16	20472	197820	64280424
Therapeutic product effect decreased	23.81	22.88	4	20484	115347	64362897
Venoocclusive liver disease	23.73	22.88	22	20466	9993	64468251
Pigmentation disorder	23.72	22.88	16	20472	4596	64473648
Bone marrow failure	23.51	22.88	49	20439	47903	64430341
Anxiety	23.49	22.88	18	20470	202631	64275613
Asthenia	23.48	22.88	223	20265	427821	64050423
Weight increased	23.42	22.88	20	20468	213328	64264916
Anaemia	23.17	22.88	202	20286	378478	64099766
Blood pressure increased	23.15	22.88	13	20475	172539	64305705

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FE02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA CS	M0001357	Antibodies, Monoclonal
FDA MoA	N0000020010	HER1 Antagonists
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
FDA EPC	N0000175664	Epidermal Growth Factor Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Secondary malignant neoplasm of colon	indication	94260004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	AGONIST	Kd	10.30		IUPHAR	DRUG LABEL

External reference:

ID	Source
D05350	KEGG_DRUG
4025701	VUID
N0000179714	NUI
4025701	VANDF
CHEMBL1201827	ChEMBL_ID
6883	IUPHAR_LIGAND_ID
8499	INN_ID
DB01269	DRUGBANK_ID
6A901E312A	UNII
263034	RXNORM
22205	MMSL
88497	MMSL
d05879	MMSL
423259008	SNOMEDCT_US
424401006	SNOMEDCT_US
D000077544	MESH_DESCRIPTOR_UI
C0879427	UMLSCUI
011743	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vectibix	HUMAN PRESCRIPTION DRUG LABEL	1	55513-954	SOLUTION	100 mg	INTRAVENOUS	BLA	28 sections
Vectibix	HUMAN PRESCRIPTION DRUG LABEL	1	55513-956	SOLUTION	400 mg	INTRAVENOUS	BLA	28 sections